Development Programs

The Medicines Company is conducting several development programs with planned and executed clinical trials.

The Medicines Company believes Angiomax will become the leading replacement for heparin in acute cardiovascular care. Heparin, an indirect thrombin inhibitor and commonly used anticoagulant, was discovered almost 100 years ago. Across studies in angioplasty, Angiomax has been shown to be better than heparin in preventing bleeding and ischemic complications such as heart attack, which are associated with angioplasty procedures.

Definition of terms:

• PCI: percutaneous coronary intervention is a general term used to describe non-surgical revascularization procedures of the coronary arteries.
• HITTS: heparin-induced thrombocytopenia and thrombosis syndrome (an allergic-like reaction to heparin)
• ACS: acute coronary syndromes, such as heart attack
• CABG: coronary artery bypass graft surgery (commonly called bypass or "open-heart" surgery)
• Neonates: prematurely born babies with active thrombosis (clotting)